Sou Hu Cai Jing·2025-12-31 13:02Group 1 - InSilico Medicine Cayman TopCo, referred to as "InSilico", officially listed on the Hong Kong Stock Exchange on December 30, with a pre-green shoe financing scale of HKD 22.77 billion and a post-green shoe financing scale of HKD 26.19 billion, assuming full exercise of the green shoe option [2] - This IPO is the largest for an AI pharmaceutical company in Hong Kong and the largest biotech IPO since 2025, reflecting strong market interest and recognition of InSilico's leadership in the AI pharmaceutical sector [2] - The offering attracted 15 cornerstone investors, including Eli Lilly, Tencent, Temasek, Schroders, UBS, Oak Tree Capital, E Fund, and Taikang Life, with international placement oversubscribed by 26.27 times and Hong Kong public offering oversubscribed by approximately 1427.37 times [2] Group 2 - CICC has been supporting InSilico since 2022, providing comprehensive cross-market services and leveraging its expertise in the TMT and pharmaceutical sectors to effectively promote the project and engage with global investors [3] - The project exemplifies CICC's capability in facilitating global capital operations for high-tech enterprises, with plans to continue providing comprehensive financial services to enhance the global competitiveness of international high-tech companies [3] - InSilico is a global AI-driven drug discovery and development company, utilizing its proprietary Pharma.AI platform to generate over 20 clinical or IND-stage assets, with three assets licensed to international pharmaceutical and healthcare companies, totaling a contract value of up to USD 2.1 billion [3]